Date Description


Immuno Cure kick off Phase I Clinical Trial in Shenzhen

A significant step for developing our PD-1-Enhanced DNA Vaccine against HIV/AIDS

Click here for details



Immuno Cure appoints new CFO

Strengthening of executive management team to propel growth strategy

Click here for details



Immuno Cure secured maximum subsidy from HKSTP

Significant funding support for HIV Vaccine Clinical Trial

Click here for details



Immuno Cure BioTech acquires Shanghai Teresa Healthcare
Integrating Electroporation Technology & DNA Vaccine Platforms

Acquisition of 92.6% of Shanghai Teresa Healthcare
Click here for details



Immuno Cure BioTech appoints new CEO

Broadening executive leadership team to accelerate growth strategy

Dr. Xia Jin appointed as new Chief Executive Officer and Executive Director of our Group

Click here for details



HKUMed discovers a novel vaccine strategy to prevent SARS-CoV-2 nasal infection

The study demonstrated that a combination of intramuscular PD1-based receptor-binding domain (RBD) DNA vaccine (PD1-RBD-DNA) prime and intranasal live attenuated influenza-based vaccine (LAIV-HK68-RBD) boost vaccination regimen induced the strongest mucosal broadly neutralising antibodies and lung resident memory CD8 T cells, which prevented live SARS-CoV-2 nasal challenges in two animal models

Click here for details



Phase I clinical study of our “ICCOV”, a novel and investigational SARS-CoV-2 DNA vaccine as a potential prophylactic vaccine for current pandemic disease COVID-19, is being conducted in the HKU Phase 1 Clinical Trials Centre located in Queen Mary Hospital. The study aims to investigate the safety and immunogenicity profile in human

Click here for details



病毒解碼系列1/疫苗+抗體 愛滋病救星



Exclusive License Agreement with The University of Hong Kong Technology Transfer Office (HKU TTO) for the patent for develop, make and sell the licensed products related to the prevention and treatment of infection of SARS-CoV-2



Exclusive License Agreement with HKU TTO for the patent for develop, make and sell the licensed products related to the Antibody against PD-1 Isoforms for cancer and inflammatory diseases



Hong Kong Scientists Make Potential HIV Treatment Breakthrough



Exclusive License Agreement with HKU TTO for the patent of PD-1-based DNA vaccine for prevention and treatment of HIV



Study sheds light on cancer prevention and immunotherapy


2014-08-27 港大研發抗腫瘤疫苗方法